Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 4/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PTAFR | P25105 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.37 |
| ▸ | PRKG1 | Q13976 | 5/20 | 0.37 |
| ▸ | RPS6KA5 | O75582 | 4/20 | 0.37 |
| ▸ | CDK1 | P06493 | 4/20 | 0.37 |
| ▸ | PRKACA | P17612 | 4/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6657423 | 0.95 | MAPT (0.38) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL6837206 | 0.95 | KMT2A (0.38) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL6842028 | 0.95 | PDE4A (0.36) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL6841607 | 0.94 | MAPT (0.36) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL6837255 | 0.94 | PDE4D (0.35) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL6844093 | 0.94 | PDE4A (0.35) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL6844146 | 0.94 | MPO (0.36) | PDE4BMAPK1ROCK2ROCK1PRKG1 | |
| SCHEMBL6841862 | 0.93 | MTTP (0.36) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL6842650 | 0.93 | PDE2A (0.35) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL6658003 | 0.92 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-1435958-A1 | USE OF PHOSPHORODIESTERASE IV INHIBITORS | MERCK PATENT GmbH (DE) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003032993-A1 | USE OF PHOSPHORODIESTERASE IV INHIBITORS | MERCK PATENT GMBH (DE) | 2003-04-24 | — | — | WO | disclosed |
| EP-0763534-B1 | Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GMBH (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-5859008-A | Arylalkyl diazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-01-12 | — | — | US | disclosed |
| EP-0763534-A1 | Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GmbH (DE) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | PDE4A, PDE3A, PDE3B | PDE4A 1/4885PDE4B 4/4885PDE4C 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.